CN1383888A - Yixinkang tablet and its prepn - Google Patents
Yixinkang tablet and its prepn Download PDFInfo
- Publication number
- CN1383888A CN1383888A CN 01142868 CN01142868A CN1383888A CN 1383888 A CN1383888 A CN 1383888A CN 01142868 CN01142868 CN 01142868 CN 01142868 A CN01142868 A CN 01142868A CN 1383888 A CN1383888 A CN 1383888A
- Authority
- CN
- China
- Prior art keywords
- radix
- hours
- fructus crataegi
- yixinkang
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to the field of Chinese medicine technology. One medicine tablet, named Yixinkang talbet, for treating blood stasis and hyperlipemia of middle edged and old aged people and preventing coronary heart disease and its preparation process is provided. it is prepared with ginseng, prepared fleeceflower root, notoginseng and haw and has the functions of promoting blood circulation to disperse blood clots, invigorating vital energy, etc.
Description
Technical field:
The invention belongs to technical field of Chinese medicines, relate to a kind of centering old man Blood stasis, blood fat disease has good improvement effect, and the Yixinkang table of prevention coronary disease pain and preparation method thereof.
Background technology:
Middle-aged and elderly people is owing to dirty, internal organs hypofunction, and the unable blood vessels of agitating show as blood stasis due to qi deficiency in various degree more; Usually be the origin of multiple disease, wherein cardiovascular and cerebrovascular disease is especially outstanding; The FUFANG DANSHEN PIAN total effective rate 56.8% of old man's Blood stasis, blood fat disease in the existing treatment, curative effect is lower.
Summary of the invention:
The purpose of this invention is to provide a kind ofly has good improvement effect to middle-aged and elderly people Blood stasis, blood fat disease, and the high Yixinkang table of curative effect and preparation method thereof.
The technical scheme that the present invention takes constitutes (by weight percentage) by following Chinese medicine: Radix Ginseng 3--9%, Radix Polygoni Multiflori Preparata 15--59%, Radix Notoginseng 8--24%, Fructus Crataegi 18--59%.
The preparation method that the present invention takes is as follows: take by weighing various medical materials accurately, with Radix Ginseng with 60% soak with ethanol 24 hours, reflux 2 hours, collect medicinal liquid, continuous backflow 5 times merges all medicinal liquids, reclaim ethanol, be concentrated into relative density 1.35 (80 ℃ of measurements), standby; The Radix Notoginseng fine powder is crossed 60 mesh sieves, and is standby; Fructus Crataegi, system He Daowu put into extraction pot, extract 4 hours for the first time, extract 3 hours for the second time, collect medicinal liquid, are concentrated into relative density 1.20 (40 ℃ of measurements) and put the spray drying tower drying, and the cream powder is standby; With Radix Notoginseng fine powder and Fructus Crataegi, system He Daowu, cream powder mixing, add Radix Ginseng extractum, 55 ℃ of dryings, pulverizing add starch and diluent 75% dealing with alcohol, and mixed pelletization was put 55 ℃ of dryings of baking oven 6 hours, granulate; Add magnesium stearate, put the tablet machine tabletting, sugar coating is through after the assay was approved; Packing.
Yixinkang table of the present invention is mainly used in blood circulation promoting and blood stasis dispelling, tonifying QI to produce body fluid, and treatment breast low pain, numb limbs and tense tendons, spiritlessness and weakness, senilism, hyperlipidemia etc., and can prevent coronary heart disease.
Middle-aged and elderly people hyperlipemia, atherosclerosis and cardiovascular and cerebrovascular disease, its clinical manifestation belongs to traditional Chinese medical science blood stasis due to qi deficiency category more, according to theory of Chinese medical science, in conjunction with clinical practice prescription for many years, wherein first-selected Radix Ginseng is monarch, and the gas of big tonifying five ZANG-organs kidney-Yang is to consolidate, the kind blood stasis dispelling blood of Radix Notoginseng is minister, the monarch and his subjects associate with, and play benefiting QI for activating blood circulation altogether, and blood stasis is dispelled, and then fresh blood is living.Radix Polygoni Multiflori Preparata invigorating the liver and kidney, benefiting essence-blood, Fructus Crataegi is assisted blood circulation promoting and blood stasis dispelling.In recent years, Chinese scholars is to " benefiting QI for activating blood circulation " rule of treatment, side's medicine has carried out a large amount of research work, has obtained progress, propose if any the scholar, the mechanism of action of blood circulation promoting and blood stasis dispelling is the oxygen deliverability of having improved tissue and cell, and oxygen is that multiple disease (comprises that senescence changes for deficiency, atherosclerosis etc.) pathogenesis is again the main mechanism that disease takes place.The vital organ of body (heart, brain) must guarantee competent oxygen confession at any time, and oxygen is for even more important than nutrition.There is the scholar to propose; The effect of Qi-tonifying drug is to improve hematodinamics, the blood circulation promoting medicine effect is to improve hemorheological property.There is research data to confirm, hyperlipemia and blood viscosity and blood stasis expectorant is turbid is proportionate, particularly outstanding in person in middle and old age's hyperlipidemia.According to research reports, hyperlipemia can promote platelet aggregation, and forms the blood stasis state, therefore, blood circulation promoting and blood stasis dispelling is to preventing playing an important role of atherosclerotic lesion, the four Chinese medicine thing that we select, independent clinical and experimentation shows, all blood fat reducing effects.The gas of the big tonifying five ZANG-organs kidney-Yang of Radix Ginseng, traditional Chinese medical science what is called " vital qi " is the healthy energy of human body, is equivalent to the described immune function of human body of modern medicine.Radix Ginseng not only has the cholesterol regulating metabolism, suppresses the hypercholesterolemia effect, and obviously increases red, the leukocyte of human body, the quantity of hemoglobin, the short gonadotropic Effect of tool cardiotonic glycoside sample and class simultaneously.Radix Notoginseng has coronary artery dilating, coronary blood flow increasing, and does not increase myocardial oxygen consumption, improves effects such as myocardium microcirculation, heart tonifying, blood fat reducing.The blood fat reducing of Radix Polygoni Multiflori Preparata tool reduces the absorption of cholesterol at intestinal, and the enhancing immune function of human body is arranged.In research in the past, discovery is that the Qibao Meiran Dan of main component has the effect that improves aging relevant enzyme SOD and reduce LPO with the Radix Polygoni Multiflori.The effective ingredient of Fructus Crataegi is a total flavones, and the effect of similar Radix Notoginseng is arranged.And, also observed with containing of Fructus Crataegi fine powder, obvious effect for reducing blood fat is arranged.Radix Polygoni Multiflori Preparata and the Fructus Crataegi superoxide dismutase (SOD) that is improved is active and increase the vigor of endogenous free radical cleaning system, suppresses the generation of LPO, makes its decline, and therefore, the blood fat reducing treatment also can be fallen LPO simultaneously.
Description of drawings:
Fig. 1 is a process chart of the present invention.
The specific embodiment:
One of prescription: Radix Ginseng 3%, Radix Polygoni Multiflori Preparata 15%, Radix Notoginseng 24%, Fructus Crataegi 57%;
Two of prescription: Radix Ginseng 9%, Radix Polygoni Multiflori Preparata 59%, Radix Notoginseng 8%, Fructus Crataegi 22%;
Three of prescription: Radix Ginseng 9%, Radix Polygoni Multiflori Preparata 20%, Radix Notoginseng 10%, Fructus Crataegi 59%;
Four of prescription: Radix Ginseng 9%, Radix Polygoni Multiflori Preparata 50%, Radix Notoginseng 22%, Fructus Crataegi 18%;
Claims (2)
1, a kind of Yixinkang table constitutes (by weight percentage) by following Chinese medicine: Radix Ginseng 3--9%, Radix Polygoni Multiflori Preparata 15--59%, Radix Notoginseng 8--24%, Fructus Crataegi 18--59%.
2, a kind of preparation method of Yixinkang table, the preparation method taked are as follows: take by weighing various medical materials accurately, with Radix Ginseng with 60% soak with ethanol 24 hours, reflux 2 hours, collect medicinal liquid, continuous backflow 5 times merges all medicinal liquids, reclaims ethanol, be concentrated into relative density 1.35 (80 ℃ of measurements), standby; The Radix Notoginseng fine powder is crossed 60 mesh sieves, and is standby; Fructus Crataegi, system He Daowu put into extraction pot, extract 4 hours for the first time, extract 3 hours for the second time, collect medicinal liquid, are concentrated into relative density 1.20 (40 ℃ of measurements) and put the spray drying tower drying, and the cream powder is standby; With Radix Notoginseng fine powder and Fructus Crataegi, system He Daowu, cream powder mixing, add Radix Ginseng extractum, 55 ℃ of dryings, pulverizing add starch and diluent 75% dealing with alcohol, and mixed pelletization was put 55 ℃ of dryings of baking oven 6 hours, granulate; Add magnesium stearate, put the tablet machine tabletting, sugar coating is through after the assay was approved; Packing.(by weight percentage) that constitutes by following Chinese medicine: Radix Ginseng 3--9%, Radix Polygoni Multiflori Preparata 15--59%, Radix Notoginseng 8--24%, Fructus Crataegi 18--59%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01142868 CN1383888A (en) | 2001-12-31 | 2001-12-31 | Yixinkang tablet and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01142868 CN1383888A (en) | 2001-12-31 | 2001-12-31 | Yixinkang tablet and its prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1383888A true CN1383888A (en) | 2002-12-11 |
Family
ID=4676997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01142868 Pending CN1383888A (en) | 2001-12-31 | 2001-12-31 | Yixinkang tablet and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1383888A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006060951A1 (en) * | 2004-12-10 | 2006-06-15 | Tianjin Tasly Pharmaceutical Co., Ltd. | A pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof |
| CN1298348C (en) * | 2005-05-31 | 2007-02-07 | 马耀茹 | Injection for treating coronary heart disease and cerebral infarction |
| CN102225107A (en) * | 2011-06-22 | 2011-10-26 | 河南省中医药研究院 | Yixin xuezhikang capsule |
| CN108578578A (en) * | 2018-07-25 | 2018-09-28 | 湖南新汇制药股份有限公司 | A kind of pharmaceutical composition and preparation method thereof |
-
2001
- 2001-12-31 CN CN 01142868 patent/CN1383888A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006060951A1 (en) * | 2004-12-10 | 2006-06-15 | Tianjin Tasly Pharmaceutical Co., Ltd. | A pharmaceutical composition for the treatment and/or prevention of hyperlipidemia, processes for producing the same and the use thereof |
| US8747913B2 (en) | 2004-12-10 | 2014-06-10 | Tasly Pharmaceutical Group Co., Ltd | Herbal extract pharmaceutical composition and method for treating and/or preventing of hyperlipidemia and processes for producing the same |
| CN1298348C (en) * | 2005-05-31 | 2007-02-07 | 马耀茹 | Injection for treating coronary heart disease and cerebral infarction |
| CN102225107A (en) * | 2011-06-22 | 2011-10-26 | 河南省中医药研究院 | Yixin xuezhikang capsule |
| CN102225107B (en) * | 2011-06-22 | 2013-06-12 | 河南省中医药研究院 | Yixin xuezhikang capsule |
| CN108578578A (en) * | 2018-07-25 | 2018-09-28 | 湖南新汇制药股份有限公司 | A kind of pharmaceutical composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102247530A (en) | Tall gastrodia tuber spirit for resisting fatigue and enhancing immunity | |
| CN103372135B (en) | Chinese medicinal composition treating cardiovascular and cerebrovascular diseases caused by heart-kidney imbalance | |
| CN101032599B (en) | Healthy solution for conditioning skin and losing weight | |
| CN102688472B (en) | Medicinal composition for preventing or relieving yang deficiency syndrome of tumor patient | |
| CN1301123C (en) | Medicine for treating female menstrual disorder (stagnancy of qi and blood stasis) | |
| CN101391056B (en) | Medicine for treating aplastic anemia | |
| CN101979013B (en) | Traditional Chinese medicine for treating leukemia | |
| CN100488539C (en) | Pharmaceutical composition for promoting blood circulation and preparation method thereof | |
| CN1383888A (en) | Yixinkang tablet and its prepn | |
| CN103599455B (en) | Traditional Chinese medicine capsule for removing freckle | |
| CN103182008A (en) | Preparation method for traditional Chinese medicine used for stabilizing and reducing blood pressure | |
| CN1836716A (en) | Health oral liquid | |
| CN105456710B (en) | A kind of blood activating and fat reducing medicine and preparation method thereof | |
| CN101032619A (en) | Liquid medicine to be taken orally for curing primary hypertension and the preparing method | |
| CN1132606C (en) | Medicine for curing coronary heart disease with hypertension and its preparation process | |
| CN1319555C (en) | Medicine for treating prostate hyperplasia and method of preparing the same | |
| CN1772119A (en) | Medicine for treating coronary heart disease and angina pectoris and its prepn | |
| CN103495115B (en) | A kind of to the medicative medicated wine of diabetes tool | |
| CN1124857C (en) | Chinese medicine prepn for treating cerebral thrombus, hypertension and cerebral arteriosclerosis and its production process | |
| CN106334065A (en) | Edible and medicinal traditional Chinese medicine formula used for treating gynecological diseases and having beauty effect and production process | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN101284059A (en) | Chinese medicinal materials preparation for reinforcing the spleen and kidney and curing the chronic nephritis | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN114767794B (en) | Traditional Chinese medicine for treating arterial plaque | |
| CN1247228C (en) | Method for preparing Qi-benefiting and blood circulation-promoting pill for treating insufficienty of heart-qi coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |